Open AccessTicagrelor Use in Stroke Patients: Past, Present, and Future
Author(s) -
Rahul Chandra,
Harneel Saini,
Russell Cerejo,
Ashis Tayal,
Konark Malhotra
Publication year - 2021
Publication title -
vascular health and risk management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.892
H-Index - 68
eISSN - 1178-2048
pISSN - 1176-6344
DOI - 10.2147/vhrm.s266968
Subject(s) - ticagrelor , medicine , clopidogrel , prasugrel , aspirin , stroke (engine) , dipyridamole , platelet aggregation inhibitor , antiplatelet drug , cardiology , intensive care medicine , mechanical engineering , engineering
Antiplatelet medications are the mainstay for secondary stroke treatment. Aspirin, clopidogrel, and aspirin-dipyridamole are commonly used antiplatelet medications. Other antiplatelet medications such as ticagrelor and prasugrel have been majorly used in cardiovascular or neuro-interventional specialties. Recent studies have paved a way to their use in secondary stroke prevention. In this review, we have briefly discussed the pharmacology of ticagrelor, published literature in cardiology and stroke trials, use of ticagrelor among patients with ischemic strokes, and compared its efficacy, limitations and side-effects with other antiplatelet medications.